Related Experiment Videos
Cerebral venous and sinus thrombosis
F Masuhr1, S Mehraein, K Einhäupl
1Dept. of Neurology, Charité Medical School, Humboldt-Universität, Schumannstrasse 20/21, 10117 Berlin, Germany.
Journal of Neurology
|March 5, 2004
Summary
Cerebral venous and sinus thrombosis (CVST) has a better prognosis than previously thought, with over 80% survival. Anticoagulation is the preferred first-line treatment for CVST, reducing risks of death and disability.
Area of Science:
- Neurology
- Vascular Medicine
- Thrombosis Research
Background:
- Cerebral venous and sinus thrombosis (CVST) presents with diverse symptoms, from headache to coma.
- Historically, CVST prognosis was considered poor, but recent studies indicate over 80% survival.
- Predicting individual patient recovery is challenging, but admission clinical status and neuroimaging are key prognostic indicators.
Purpose of the Study:
- To review the current understanding of cerebral venous and sinus thrombosis (CVST).
- To evaluate prognostic factors and treatment strategies for CVST.
- To assess the risk of recurrence and long-term management of CVST.
Main Methods:
- Review of prospective studies and available treatment data from controlled trials on CVST.
- Analysis of clinical presentation and neuroimaging findings as prognostic factors.
- Evaluation of anticoagulation (AC) as a primary treatment modality for CVST.
Main Results:
- Clinical presentation and neuroimaging are crucial for prognosis; comatose patients with intracranial hemorrhage face the highest risk.
- Anticoagulation (AC) is favored as first-line therapy, reducing mortality and disability without increasing hemorrhage risk.
- Recurrence risk is low (<10%), typically within 12 months; long-term AC benefits require further controlled data.
Conclusions:
- CVST prognosis is generally favorable with prompt diagnosis and appropriate management.
- Anticoagulation is the cornerstone of CVST treatment, with potential for more aggressive therapies in refractory cases.
- While recurrence is uncommon, optimal duration of anticoagulation, especially in thrombophilia, needs further investigation.